RGEN as of Nov 2 · 05:07 ET
RGENNasdaqBiological Products, (No Diagnostic Substances)
Repligen Corp · Brief
Next report
113 days
Feb 23 · before openest.Q4 FY26
Expected move
No implied move.
—≥ implied
Apr 29 '25—▼−2.92%—
Jul 29 '25—▲+4.72%—
Oct 28 '25—▼−5.92%—
Feb 24 '26—▼−0.54%—
Q1 FY26—▲+6.26%—
Q2 FY26—▲+2.26%—
Jul 28 '26—▲+10.90%—
Q3 FY26±11.7%▼−2.43%×0.21
quarterimplied−15%0+15%realized×
Q3 FY26±11.7%▼−2.43%×0.21
Jul '26—▲+10.90%—
Q2 FY26—▲+2.26%—
Q1 FY26—▲+6.26%—
Feb '26—▼−0.54%—
Oct '25—▼−5.92%—
2 older reports
Jul '25—▲+4.72%—
Apr '25—▼−2.92%—
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close
Bull & bear
Feb 23 report · est.—
Linked exposure
RGEN report sessionNo linked exposure.
Your note
privateThesis 0 · Decisions 0 · Observations 0
No thesis.